Get the Stockscreener App
3.8101
0.29%
0.0101
Pyxis Oncology Inc stock is traded at $3.8101, with a volume of 147.62K.
It is up +0.29% in the last 24 hours and up +7.66% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$3.80
Open:
$3.78
24h Volume:
147.62K
Relative Volume:
0.31
Market Cap:
$225.81M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-1.3416
EPS:
-2.84
Net Cash Flow:
$-77.44M
1W Performance:
-0.24%
1M Performance:
+7.66%
6M Performance:
-12.99%
1Y Performance:
+116.53%
1-Day Range:
$3.73
$3.861
1-Week Range:
$3.56
$3.94
52-Week Range:
$1.35
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by abrdn plc - MarketBeat
Pyxis Oncology Inc (PYXS) Stock Price & Chart | Trade Now - Capital.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Pyxis Oncology expands equity plan by 5.5 million shares - Investing.com India
Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Financial Metrics Exploration: Understanding Pyxis Oncology Inc (PYXS) Through Ratios - The Dwinnex
Examining Pyxis Oncology Inc (PYXS) stock is warranted - US Post News
Millennium Management LLC Buys 743,499 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
Upward Trajectory: Pyxis Oncology Inc (PYXS) Posts a Slidee, Closing at 3.51 - The Dwinnex
Pyxis Oncology's SWOT analysis: ADC developer's stock faces pivotal readout - Investing.com
Rhumbline Advisers Takes Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Blue Owl Capital Holdings LP Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - PR Newswire
ShiftPixy stock plunges to 52-week low at $0.9 amid market challenges - Investing.com
Prepare Yourself for Liftoff: Pyxis Oncology Inc (PYXS) - SETE News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Bank of New York Mellon Corp - MarketBeat
ShiftPixy, Inc. Announces Reverse Stock Split Effective Date - Business Wire
Are Pyxis Oncology Inc’shares a good deal? - US Post News
Pyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Market Insights: Pyxis Oncology Inc (PYXS)’s Notable Gain of 1.39, Closing at 3.66 - The Dwinnex
Earth Science Tech (OTCMKTS:ETST) vs. Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Comparison - Defense World
Moment Of Truth Approaches For Pyxis Oncology (NASDAQ:PYXS) - Seeking Alpha
Pyxis Oncology : Morgan Stanley 22nd Annual Global Healthcare Conference - Marketscreener.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Pyxis Oncology Inc (PYXS) looking to reclaim success with recent performance - SETE News
Have you been able to find a good deal on Pyxis Oncology Inc’s shares? - US Post News
Quarterly Snapshot: Quick and Current Ratios for Pyxis Oncology Inc (PYXS) - The Dwinnex
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewswire
JAZZ: 3 Oncology Stocks With Major Upside - StockNews.com
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024 - MSN
Market Momentum Report: Pyxis Oncology Inc (PYXS)’s Positive Close at 3.62 - The Dwinnex
Q3 2024 EPS Estimates for Pyxis Oncology, Inc. Boosted by William Blair (NASDAQ:PYXS) - MarketBeat
What is the investor’s view on Pyxis Oncology Inc (PYXS)? - US Post News
Cetera Advisors LLC Makes New $100,000 Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Q3 2024 Earnings Estimate for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William Blair - Defense World
Vanguard Group Inc. Acquires 94,740 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology maintains steady target with Buy rating from H.C. Wainwright - Investing.com India
Market Insight: Pyxis Oncology Inc (PYXS)’s Notable Gain, Closing at 3.43 - The Dwinnex
Pyxis Oncology (NASDAQ:PYXS) Earns “Buy” Rating from HC Wainwright - Defense World
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 - GlobeNewswire
Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.00 - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pyxis Oncology stock gains as Stifel says buy (NASDAQ:PYXS) - Seeking Alpha
Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat
What was Pyxis Oncology Inc (PYXS)’s performance in the last session? - US Post News
Stifel sets $10 target on Pyxis Oncology, cites unique approach - Investing.com
Market Recap Check: Pyxis Oncology Inc (PYXS)’s Positive Finish at 3.37, Up/Down 3.69 - The Dwinnex
Pyxis Oncology Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$203m - Simply Wall St
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):